|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
intramuscular injection
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
gptkb:J07BX02
|
|
gptkbp:brand
|
gptkb:Ervebo
|
|
gptkbp:clinicalTrialPhase
|
gptkb:Ebola_ça_Suffit!
|
|
gptkbp:contains
|
gptkb:recombinant_vesicular_stomatitis_virus
glycoprotein of Zaire ebolavirus
|
|
gptkbp:contraindication
|
severe allergic reaction to vaccine components
|
|
gptkbp:countryOfOrigin
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Merck
|
|
gptkbp:form
|
solution for injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rVSV-ZEBOV
|
|
gptkbp:indication
|
prevention of Ebola virus disease
|
|
gptkbp:notRecommendedFor
|
children under 18 years (initial approval)
pregnant women (initial approval)
|
|
gptkbp:routeOfAdministration
|
intramuscular
|
|
gptkbp:sideEffect
|
fever
headache
muscle pain
injection site pain
|
|
gptkbp:storage
|
-80°C to -60°C
|
|
gptkbp:target
|
gptkb:Zaire_ebolavirus
|
|
gptkbp:usedInOutbreak
|
gptkb:2014–2016_West_Africa_Ebola_outbreak
gptkb:2018–2020_Kivu_Ebola_outbreak
|
|
gptkbp:WHOPrequalified
|
2019
|
|
gptkbp:bfsParent
|
gptkb:vaccine
|
|
gptkbp:bfsLayer
|
4
|